1. VIM‑AS1 promotes proliferation and drives enzalutamide resistance in prostate cancer via IGF2BP2‑mediated HMGCS1 mRNA stabilization.
   Sheng-Jia Shi et al, 2023, Int J Oncol CrossRef
2. Clinical implications of lncRNA LINC-PINT in cancer
   Ihtisham Bukhari et al, 2023, Front. Mol. Biosci. CrossRef
3. CREB-induced LINC00473 promotes chemoresistance to TMZ in glioblastoma by regulating O6-methylguanine-DNA-methyltransferase expression via CEBPα binding
   Li-Ya Jiang et al, 2023, Neuropharmacology CrossRef
4. Nanoparticles for efficient drug delivery and drug resistance in glioma: New perspectives
   Jiyuan Liu et al, 2024, CNS Neurosci Ther CrossRef
5. KHDRBS3 facilitates self-renewal and temozolomide resistance of glioblastoma cell lines
   Kanokkuan Somrit et al, 2024, Life Sciences CrossRef